Rx Nutrition Resource Center
Rx Nutrition Resource Center
June 11, 2019
1 min read

Vitamin D fails at diabetes prevention

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

SAN FRANCISCO — Adults with prediabetes who received daily vitamin D supplementation for 2.5 years were just as likely to develop type 2 diabetes during follow-up as similar patients who received placebo, regardless of baseline vitamin D status, according to study data presented at the American Diabetes Association Scientific Sessions and published in The New England Journal of Medicine.

“We specifically designed the study to be agnostic to the 25-hydroxyvitamin D levels at baseline, but also during the study in real time,” Anastassios G. Pittas, MD, co-director of the Diabetes and Lipid Center and professor at Tufts University School of Medicine, Boston, said during the presentation.

Researchers analyzed data from 2,423 participants older than 30 years with BMIs between 24 kg/m² and 42 kg/m² with at least two of three glycemic criteria for prediabetes.

At 24 months, mean serum 25-(OH)D level was 54.3 ng/mL in the vitamin D group vs. 28.8 ng/mL in the placebo group. After a median of 2.5 years, new-onset diabetes was noted in 293 participants in the vitamin D group vs. 323 participants in the placebo group.

In addition, the HR for new-onset diabetes for patients receiving vitamin D was 0.88 (95% CI, 0.75-1.04), and neither group experienced significantly more kidney stones, high serum calcium or high glomerular filtration rate.

For more Healio coverage of this study, please click here. – by Janel Miller and Regina Schaffer


Pittas AG, et al. The Vitamin D and Type 2 Diabetes (D2d) study — a multicenter randomized controlled trial for diabetes prevention. Presented at: American Diabetes Association 79th Scientific Sessions; June 7-11, 2019; San Francisco.


Pittas AG, et al. N Engl J Med. 2019;doi:10.1056/NEJMoa1900906.

Wexler DJ. N Engl J Med. 2019;doi:10.1056/NEJMe1906815.

Disclosures: Pittas and Staten report no relevant financial disclosures. Please see the study for all other authors’ relevant financial disclosures. Wexler reports she has served on a data monitoring committee for Novo Nordisk.